Fiducial Markers for Lung and Prostate Cancer in Europe and US, Forecast to 2022

Fiducial Markers for Lung and Prostate Cancer in Europe and US, Forecast to 2022

Improved Accuracy for Localization of Radiotherapy Treatment to Drive the Demand for Fiducial Markers

RELEASE DATE
29-May-2019
REGION
North America
Research Code: 9AB9-00-A8-00-00
SKU: HC03177-NA-MR_23232

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC03177-NA-MR_23232

$1,500.00

$1,125.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

15 to 20 million new cases of cancer are diagnosed every year. Radiotherapy is the gold standard for treatment and is used on more than 3.5 million people and provided as palliative or adjunct treatment for an additional 3.5 million people, worldwide. Nearly 50 percent of all cancer patients are estimated to benefit from radiotherapy for disease management. Radiotherapy is used in cancers that are localized; it can provide excellent control with no recurrence in the treated area. Radiotherapy is also frequently used in combination with surgery or with chemotherapy.

As radiotherapy is a more cost-effective cancer treatment modality, expanding the services of radiotherapy is necessary to providing effective treatment strategies for cancer across care settings. Delivery of radiotherapy with high accuracy and precision—to reduce injury to normal tissues—is the need of the hour. Fiducial markers enable providers to accurately locate tumor lesions and deliver localized and targeted radiotherapy with higher accuracy. Implantation of gold fiducial markers is a cost-effective method. Complications from fiducial marker implantation are not common. Migration of implanted markers is rare and clinically insignificant. Fiducial markers are now considered the standard of care in the delivery of modern prostate RT, and their use is recommended, especially at dose escalation. Fiducials are an excellent surrogate for prostate position and allow for accurate treatment delivery and minimize the effect of radiation on surrounding organs. The main purpose of using fiducial markers is to increase treatment precision where tracking a tumor is difficult. Fiducial markers are commonly used in prostate and lung cancer and are still in the early stages of being used in the treatment of breast, liver and pancreatic cancer.

Lack of clarity on reimbursement, patient selection, lack of training and skill set, and adoption of CBCT are the main challenges to widespread adoption of fiducial markers. On the other hand, easy implantation, low cost, potential for use in future diagnostic purpose, and well-established clinical evidence serve as major driving factors. The research service provides an end-user and market perspective for the use of fiducial markers in US and Europe and provides a five-year forecast from 2017 to 2022. The unique value of this study is that it provides insights gathered from more than 150 end users, including oncologists, interventional radiologists, radiation oncologists, urologists, and pulmonologists. The key applications covered in the report include breast cancer, liver cancer, prostate cancer, lung cancer, and pancreatic cancer. In depth analysis is provided for prostate and lung cancer.

Author: Sowmya Rajagopalan

Table of Contents

Executive Summary—Fiducial Markers Market in the United States and Europe

US and European Fiducial Markers Market Summary

Research Scope and Segmentation

US and EU Fiducial Markers Market—Cancer Type Snapshot

EU and US Fiducial Markers Market—Summary

Overview

Infrastructure, Prevalence, and Incidence Statistics

Procedural Volume Breakdown

Utilization of Radiotherapy in Cancer Treatment

Revenue Forecast

US Fiducial Markers Market Explained

Market Share Analysis

Procedure Cost and Reimbursement

Cancer Treatment Procedural Volume by Practice Size

Budget Allocation and Radiotherapy Procedural Volume

Annual Budget Allocation and Spending on Fiducial Markers

Introduction of Fiducial Markers to Professionals

Services that Professionals Require of Manufacturers

Patient Indication for Using Fiducials in Prostate and Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer (Continued)

Fiducial Marker Usage in the Treatment of Prostrate Cancer

Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)

Placement of Fiducial Markers

Ideal Fiducial Marker Cost and Patient Adoption

Key Factors for not Using Fiducial Markers—Lung Cancer

Key Factors for not Using Fiducial Markers—Prostate Cancer

Key Challenges with Existing Fiducial Markers—Lung Cancer

Key Challenges with Existing Fiducials—Prostate Cancer

Key Criteria for Ideal Fiducial Marker—Lung Cancer

Key Criteria for Ideal Fiducial Marker—Prostate Cancer

Fiducial Marker Type Preferences for Prostate and Lung Cancer

End-user Perspective—Liquid Markers

End-user Perspective—CBCT

Endoscopy Approach and Use of Fiducials in MI Surgery

Image Guidance in the Treatment of Cancer

Key Buying Criteria

Impact of Fiducial Marker Adoption—Applications and Potential Use

Overview

Procedural Infrastructure, Prevalence, and Incidence

Procedural Volume Breakdown

Utilization of Radiotherapy in Cancer Treatment

German Fiducial Markers Market Snapshot

German Fiducial Markers Market Explainedncrease.

Market Share Analysis

Procedure Cost and Reimbursement

Cancer Treatment Procedural Volume by Practice Size

Budget Allocation and Radiotherapy Procedural Volume

Annual Budget Allocation and Spending on Fiducial Markers

Introduction of Fiducial Markers to Professionals

Services that Professionals Require of Manufacturers

Patient Indication for Using Fiducials in Prostate and Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer (continued)

Fiducial Marker Usage in the Treatment of Prostrate Cancer

Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)

Placement of Fiducial Markers

Ideal Fiducial Marker Cost and Patient Adoption

Key Factors that Affect Use of Fiducials—Lung Cancer

Key Factors that Affect Use of Fiducials—Prostate Cancer

Key Challenges with Existing Fiducials—Lung Cancer

Key Challenges with Existing Fiducials—Prostate Cancer

Important Criteria for Ideal Fiducial Marker—Lung Cancer

Important Criteria for Ideal Fiducial Marker—Prostate Cancer

Fiducial Marker Type Preferences for Prostate and Lung Cancer

End-user Perspective—Liquid Markers

End-user Perspective—CBCT

Endoscopy Approach and Use of Fiducials in MI Surgery

Image Guidance in the Treatment of Cancer

Key Brand Selection Criteria

Impact of Fiducial Marker Adoption—Applications and Potential Use

Overview

Infrastructure, Prevalence, and Incidence Statistics

Procedural Volume Breakdown

Utilization of Radiotherapy in Cancer Treatment

French Fiducial Markers Market Snapshot

French Fiducial Markers Market Explained

Market Share Analysis

Procedure Cost and Reimbursement

Cancer Treatment Procedural Volume by Practice Size

Budget Allocation and Radiotherapy Procedural Volume

Annual Budget Allocation and Spending on Fiducial Markers

Introduction of Fiducial Markers to Professionals

Services that Professionals Require of Manufacturers

Patient Indication for Using Fiducials in Prostate and Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer (Continued)

Fiducial Marker Usage in the Treatment of Prostrate Cancer

Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)

Placement of Fiducial Markers

Ideal Fiducial Marker Cost and Patient Adoption

Key Factors that Affect Use of Fiducials—Lung Cancer

Key Factors that Affect Use of Fiducials—Prostate Cancer

Key Challenges with Existing Fiducials—Lung Cancer

Key Challenges with Existing Fiducials—Prostate Cancer

Important Criteria for Ideal Fiducial Marker—Lung Cancer

Important Criteria for Ideal Fiducial Marker—Prostate Cancer

Fiducial Marker Type Preferences for Prostate and Lung Cancer

End-user Perspective—Liquid Markers

End-user Perspective—CBCT

Endoscopy Approach and Use of Fiducials in MI Surgery

Image Guidance in the Treatment of Cancer

Key Brand Selection Criteria

Impact of Fiducial Marker Adoption—Applications and Potential Use

Overview

Infrastructure, Prevalence, and Incidence Statistics

Procedural Volume Breakdown

Utilization of Radiotherapy in Cancer Treatment

UK Fiducial Markers Market Snapshot

UK Fiducial Markers Market Explained

Market Share Analysis

Procedure Cost and Reimbursement

Cancer Treatment Procedural Volume by Practice Size

Budget Allocation and Radiotherapy Procedural Volume

Annual Budget Allocation and Spending on Fiducial Markers

Introduction of Fiducial Markers to Professionals

Services that Professionals Require of Manufacturers

Patient Indication for Using Fiducials in Prostate and Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer (continued)

Fiducial Marker Usage in the Treatment of Prostrate Cancer

Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)

Placement of Fiducial Markers

Ideal Fiducial Marker Cost and Patient Adoption

Key Factors that Affect Use of Fiducials—Lung Cancer

Key Factors that Affect Use of Fiducials—Prostate Cancer

Key Challenges with Existing Fiducials—Lung Cancer

Key Challenges with Existing Fiducials—Prostate Cancer

Important Criteria for Ideal Fiducial Marker—Lung Cancer

Important Criteria for Ideal Fiducial Marker—Prostate Cancer

Fiducial Marker Type Preferences for Prostate and Lung Cancer

End-user Perspective—Liquid Markers

End-user Perspective—CBCT

Endoscopy Approach and Use of Fiducials in MI Surgery

Image Guidance in the Treatment of Cancer

Key Brand Selection Criteria

Impact of Fiducial Marker Adoption—Applications and Potential Use

Overview

Infrastructure, Prevalence, and Incidence Statistics

Procedural Volume Breakdown

Utilization of Radiotherapy in Cancer Treatment

Italian Fiducial Markers Market Snapshot

Italian Fiducial Markers Market Explained

Market Share Analysis

Procedure Cost and Reimbursement

Cancer Treatment Procedural Volume by Practice Size

Budget Allocation and Radiotherapy Procedural Volume

Annual Budget Allocation and Spending on Fiducial Markers

Introduction of Fiducial Markers to Professionals

Services that Professionals Require of Manufacturers

Patient Indication for Using Fiducials in Prostate and Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer (continued)

Fiducial Marker Usage in the Treatment of Prostrate Cancer

Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)

Placement of Fiducial Markers

Ideal Fiducial Marker Cost and Patient Adoption

Key Factors that Affect Use of Fiducials—Lung Cancer

Key Factors that Affect Use of Fiducials—Prostate Cancer

Key Challenges with Existing Fiducials—Lung Cancer

Key Challenges with Existing Fiducials—Prostate Cancer

Important Criteria for Ideal Fiducial Marker—Lung Cancer

Important Criteria for Ideal Fiducial Marker—Prostate Cancer

Fiducial Marker Type Preferences for Prostate and Lung Cancer

End-user Perspective—Liquid Markers

End-user Perspective—CBCT

Endoscopy Approach and Use of Fiducials in MI Surgery

Image Guidance in the Treatment of Cancer

Key Brand Selection Criteria

Impact of Fiducial Marker Adoption—Applications and Potential Use

Overview

Infrastructure, Prevalence, and Incidence Statistics

Procedural Volume Breakdown

Utilization of Radiotherapy in Cancer Treatment

Spanish Fiducial Markers Market Snapshot

Spanish Fiducial Markers Market Explained

Market Share Analysis

Procedure Cost and Reimbursement

Cancer Treatment Procedural Volume by Practice Size

Budget Allocation and Radiotherapy Procedural Volume

Annual Budget Allocation and Spending on Fiducial Markers

Introduction of Fiducial Markers to Professionals

Services that Professionals Require of Manufacturers

Patient Indication for Using Fiducials in Prostate and Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer (Continued)

Fiducial Marker Usage in the Treatment of Prostrate Cancer

Fiducial Marker Usage in the Treatment of Prostrate Cancer

Placement of Fiducial Markers

Ideal Fiducial Marker Cost and Patient Adoption

Key Factors that Affect Use of Fiducials—Lung Cancer

Key Factors that Affect Use of Fiducials—Prostate Cancer

Key Challenges with Existing Fiducials—Lung Cancer

Key Challenges with Existing Fiducials—Prostate Cancer

Important Criteria for Ideal Fiducial Marker—Lung Cancer

Important Criteria for Ideal Fiducial Marker—Prostate Cancer

Fiducial Marker Type Preferences for Prostate and Lung Cancer

End-user Perspective—Liquid Markers

End-user Perspective—CBCT

Endoscopy Approach and Use of Fiducials in MI Surgery

Image Guidance in the Treatment of Cancer

Key Brand Selection Criteria

Impact of Fiducial Marker Adoption—Applications and Potential Use

Overview

Infrastructure, Prevalence, and Incidence Statistics

Procedural Volume Breakdown

Utilization of Radiotherapy in Cancer Treatment

Swiss Fiducial Markers Market Snapshot

Swiss Fiducial Markers Market Explained

Swiss Fiducial Markers Market Share Analysis

Procedure Cost and Reimbursement

Cancer Treatment Procedural Volume by Practice Size

Budget Allocation and Radiotherapy Procedural Volume

Annual Budget Allocation and Spending on Fiducial Markers

Introduction of Fiducial Markers to Professionals

Services that Professionals Require of Manufacturers

Patient Indication for Using Fiducials in Prostate and Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer

Fiducial Marker Usage in the Treatment of Lung Cancer (continued)

Fiducial Marker Usage in the Treatment of Prostrate Cancer

Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)

Placement of Fiducial Markers

Ideal Fiducial Marker Cost and Patient Adoption

Key Factors that Affect Use of Fiducials—Lung Cancer

Key Factors that Affect Use of Fiducials—Prostate Cancer

Key Challenges with Existing Fiducials—Lung Cancer

Key Challenges with Existing Fiducials—Prostate Cancer

Important Criteria for Ideal Fiducial Marker—Lung Cancer

Important Criteria for Ideal Fiducial Marker—Prostate Cancer

Fiducial Marker Type Preferences for Prostate and Lung Cancer

End-user Perspective—Liquid Markers

End-user Perspective—CBCT

Endoscopy Approach and Use of Fiducials in MI Surgery

Image Guidance in the Treatment of Cancer

Key Brand Selection Criteria

Impact of Fiducial Marker Adoption—Applications and Potential Use

Growth Opportunities Critical for Future Strategy

Growth Opportunities Critical for Future Strategy (continued)

Strategic Imperatives for Success and Growth

3 Big Predictions

Legal Disclaimer

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
15 to 20 million new cases of cancer are diagnosed every year. Radiotherapy is the gold standard for treatment and is used on more than 3.5 million people and provided as palliative or adjunct treatment for an additional 3.5 million people, worldwide. Nearly 50 percent of all cancer patients are estimated to benefit from radiotherapy for disease management. Radiotherapy is used in cancers that are localized; it can provide excellent control with no recurrence in the treated area. Radiotherapy is also frequently used in combination with surgery or with chemotherapy. As radiotherapy is a more cost-effective cancer treatment modality, expanding the services of radiotherapy is necessary to providing effective treatment strategies for cancer across care settings. Delivery of radiotherapy with high accuracy and precision—to reduce injury to normal tissues—is the need of the hour. Fiducial markers enable providers to accurately locate tumor lesions and deliver localized and targeted radiotherapy with higher accuracy. Implantation of gold fiducial markers is a cost-effective method. Complications from fiducial marker implantation are not common. Migration of implanted markers is rare and clinically insignificant. Fiducial markers are now considered the standard of care in the delivery of modern prostate RT, and their use is recommended, especially at dose escalation. Fiducials are an excellent surrogate for prostate position and allow for accurate treatment delivery and minimize the effect of radiation on surrounding organs. The main purpose of using fiducial markers is to increase treatment precision where tracking a tumor is difficult. Fiducial markers are commonly used in prostate and lung cancer and are still in the early stages of being used in the treatment of breast, liver and pancreatic cancer. Lack of clarity on reimbursement, patient selection, lack of training and skill set, and adoption of CBCT are the main challenges to widespread adoption of fiducial markers. On the other hand, easy implantation, low cost, potential for use in future diagnostic purpose, and well-established clinical evidence serve as major driving factors. The research service provides an end-user and market perspective for the use of fiducial markers in US and Europe and provides a five-year forecast from 2017 to 2022. The unique value of this study is that it provides insights gathered from more than 150 end users, including oncologists, interventional radiologists, radiation oncologists, urologists, and pulmonologists. The key applications covered in the report include breast cancer, liver cancer, prostate cancer, lung cancer, and pancreatic cancer. In depth analysis is provided for prostate and lung cancer. Author: Sowmya Rajagopalan
More Information
No Index No
Podcast No
Author Brahadeesh Chandrasekaran
Industries Healthcare
WIP Number 9AB9-00-A8-00-00
Is Prebook No
GPS Codes 9600-B1,9A47-B1,9A48-B1,9A4B-B1,9837-B1